Progress of CD123 chimeric antigen receptor T cells in treatment of acute myeloid leukemia

VernacularTitle:CD123嵌合抗原受体T细胞治疗急性髓系白血病的研究进展
Author: Xiaomin LIAO ¹ ; Qi CHEN ; Zhongxin FENG
Author Information

1. 563000,遵义医学院附属医院血液科
Keywords: Leukemia; myeloid; acute; Chimeric antigen receptor T cells; CD123
From: Journal of Leukemia & Lymphoma 2018;27(10):631-635
CountryChina
Language:Chinese
Abstract: Acute myeloid leukemia (AML) is the most common type of leukemia at present. Although clinical treatment has a certain effect on this disease, most patients still die of relapse or its treatment related diseases. Nowadays, chimeric antigen receptor (CAR) T cells therapy technology has developed rapidly, and has become a hot topic in tumor immunotherapy. The high expression of CD123 in AML cells, low expression or non expression in normal hematopoietic stem cells and tissues, make more and more researchers focus on the technology of CD123+cell immunotherapy. Some studies have confirmed that CD123 CAR-T cells have a certain effect on AML, which provides a new way for clinical treatment of relapsed or refractory AML. This review summarizes the structure, production and delivery methods of CD123 CAR-T cells, and the current research status and shortcomings of CD123 CAR-T cells.